Curcumin against amyloid pathology in mental health and brain composition

Ikuo Tooyama, Nor Faeizah Ibrahim, Lina Wati Durani, Hamizah Shahirah Hamezah, Mohd Hanafi Ahmad Damanhuri, Wan Zurinah Wan Ngah, Hiroyasu Taguchi, Daijiro Yanagisawa

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Recent evidence suggests that amyloid pathology occurs 10-20 years before the clinical onset of Alzheimer's disease (AD). Accordingly, modulating abnormal amyloid-β (Aβ) aggregation is now considered as a potential therapeutic target in AD. Curcumin, a low molecular weight polyphenol derived from the well-known spice turmeric, has various pharmacological properties, including antitumor, antioxidative, antiinflammatory, and antiamyloid effects. Curcumin binds both Aβ fibrils and oligomers and inhibits Aβ aggregation as well as Aβ-related oxidative stress and inflammation. The keto-enol tautomerism of curcumin is involved in its binding to Aβ aggregates. The enol form, but not the keto form, of curcumin can bind to Aβ aggregates. When curcumin was administered to transgenic mouse models of AD, it effectively suppressed amyloid pathology in the mouse brain. However, the results of early clinical trials of curcumin for AD have been negative, probably due to its low bioavailability. Several approaches have been proposed to improve the bioavailability of curcumin.

Original languageEnglish
Title of host publicationFruits, Vegetables, and Herbs: Bioactive Foods in Health Promotion
PublisherElsevier Inc.
Pages487-505
Number of pages19
ISBN (Electronic)9780128029893
ISBN (Print)9780128029725
DOIs
Publication statusPublished - 16 May 2016

Fingerprint

Curcumin
Amyloid
Mental Health
Pathology
Brain
Alzheimer Disease
Biological Availability
Curcuma
Spices
Polyphenols
Transgenic Mice
Oxidative Stress
Anti-Inflammatory Agents
Molecular Weight
Clinical Trials
Pharmacology
Inflammation

Keywords

  • Alzheimer's disease
  • Amyloid-β
  • Aβ oligomer
  • Curcumin
  • Inflammation
  • Oxidative stress

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tooyama, I., Ibrahim, N. F., Durani, L. W., Shahirah Hamezah, H., Ahmad Damanhuri, M. H., Ngah, W. Z. W., ... Yanagisawa, D. (2016). Curcumin against amyloid pathology in mental health and brain composition. In Fruits, Vegetables, and Herbs: Bioactive Foods in Health Promotion (pp. 487-505). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-802972-5.00023-8

Curcumin against amyloid pathology in mental health and brain composition. / Tooyama, Ikuo; Ibrahim, Nor Faeizah; Durani, Lina Wati; Shahirah Hamezah, Hamizah; Ahmad Damanhuri, Mohd Hanafi; Ngah, Wan Zurinah Wan; Taguchi, Hiroyasu; Yanagisawa, Daijiro.

Fruits, Vegetables, and Herbs: Bioactive Foods in Health Promotion. Elsevier Inc., 2016. p. 487-505.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tooyama, I, Ibrahim, NF, Durani, LW, Shahirah Hamezah, H, Ahmad Damanhuri, MH, Ngah, WZW, Taguchi, H & Yanagisawa, D 2016, Curcumin against amyloid pathology in mental health and brain composition. in Fruits, Vegetables, and Herbs: Bioactive Foods in Health Promotion. Elsevier Inc., pp. 487-505. https://doi.org/10.1016/B978-0-12-802972-5.00023-8
Tooyama I, Ibrahim NF, Durani LW, Shahirah Hamezah H, Ahmad Damanhuri MH, Ngah WZW et al. Curcumin against amyloid pathology in mental health and brain composition. In Fruits, Vegetables, and Herbs: Bioactive Foods in Health Promotion. Elsevier Inc. 2016. p. 487-505 https://doi.org/10.1016/B978-0-12-802972-5.00023-8
Tooyama, Ikuo ; Ibrahim, Nor Faeizah ; Durani, Lina Wati ; Shahirah Hamezah, Hamizah ; Ahmad Damanhuri, Mohd Hanafi ; Ngah, Wan Zurinah Wan ; Taguchi, Hiroyasu ; Yanagisawa, Daijiro. / Curcumin against amyloid pathology in mental health and brain composition. Fruits, Vegetables, and Herbs: Bioactive Foods in Health Promotion. Elsevier Inc., 2016. pp. 487-505
@inbook{43e3085d44f645a5b041c83efb2166dc,
title = "Curcumin against amyloid pathology in mental health and brain composition",
abstract = "Recent evidence suggests that amyloid pathology occurs 10-20 years before the clinical onset of Alzheimer's disease (AD). Accordingly, modulating abnormal amyloid-β (Aβ) aggregation is now considered as a potential therapeutic target in AD. Curcumin, a low molecular weight polyphenol derived from the well-known spice turmeric, has various pharmacological properties, including antitumor, antioxidative, antiinflammatory, and antiamyloid effects. Curcumin binds both Aβ fibrils and oligomers and inhibits Aβ aggregation as well as Aβ-related oxidative stress and inflammation. The keto-enol tautomerism of curcumin is involved in its binding to Aβ aggregates. The enol form, but not the keto form, of curcumin can bind to Aβ aggregates. When curcumin was administered to transgenic mouse models of AD, it effectively suppressed amyloid pathology in the mouse brain. However, the results of early clinical trials of curcumin for AD have been negative, probably due to its low bioavailability. Several approaches have been proposed to improve the bioavailability of curcumin.",
keywords = "Alzheimer's disease, Amyloid-β, Aβ oligomer, Curcumin, Inflammation, Oxidative stress",
author = "Ikuo Tooyama and Ibrahim, {Nor Faeizah} and Durani, {Lina Wati} and {Shahirah Hamezah}, Hamizah and {Ahmad Damanhuri}, {Mohd Hanafi} and Ngah, {Wan Zurinah Wan} and Hiroyasu Taguchi and Daijiro Yanagisawa",
year = "2016",
month = "5",
day = "16",
doi = "10.1016/B978-0-12-802972-5.00023-8",
language = "English",
isbn = "9780128029725",
pages = "487--505",
booktitle = "Fruits, Vegetables, and Herbs: Bioactive Foods in Health Promotion",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Curcumin against amyloid pathology in mental health and brain composition

AU - Tooyama, Ikuo

AU - Ibrahim, Nor Faeizah

AU - Durani, Lina Wati

AU - Shahirah Hamezah, Hamizah

AU - Ahmad Damanhuri, Mohd Hanafi

AU - Ngah, Wan Zurinah Wan

AU - Taguchi, Hiroyasu

AU - Yanagisawa, Daijiro

PY - 2016/5/16

Y1 - 2016/5/16

N2 - Recent evidence suggests that amyloid pathology occurs 10-20 years before the clinical onset of Alzheimer's disease (AD). Accordingly, modulating abnormal amyloid-β (Aβ) aggregation is now considered as a potential therapeutic target in AD. Curcumin, a low molecular weight polyphenol derived from the well-known spice turmeric, has various pharmacological properties, including antitumor, antioxidative, antiinflammatory, and antiamyloid effects. Curcumin binds both Aβ fibrils and oligomers and inhibits Aβ aggregation as well as Aβ-related oxidative stress and inflammation. The keto-enol tautomerism of curcumin is involved in its binding to Aβ aggregates. The enol form, but not the keto form, of curcumin can bind to Aβ aggregates. When curcumin was administered to transgenic mouse models of AD, it effectively suppressed amyloid pathology in the mouse brain. However, the results of early clinical trials of curcumin for AD have been negative, probably due to its low bioavailability. Several approaches have been proposed to improve the bioavailability of curcumin.

AB - Recent evidence suggests that amyloid pathology occurs 10-20 years before the clinical onset of Alzheimer's disease (AD). Accordingly, modulating abnormal amyloid-β (Aβ) aggregation is now considered as a potential therapeutic target in AD. Curcumin, a low molecular weight polyphenol derived from the well-known spice turmeric, has various pharmacological properties, including antitumor, antioxidative, antiinflammatory, and antiamyloid effects. Curcumin binds both Aβ fibrils and oligomers and inhibits Aβ aggregation as well as Aβ-related oxidative stress and inflammation. The keto-enol tautomerism of curcumin is involved in its binding to Aβ aggregates. The enol form, but not the keto form, of curcumin can bind to Aβ aggregates. When curcumin was administered to transgenic mouse models of AD, it effectively suppressed amyloid pathology in the mouse brain. However, the results of early clinical trials of curcumin for AD have been negative, probably due to its low bioavailability. Several approaches have been proposed to improve the bioavailability of curcumin.

KW - Alzheimer's disease

KW - Amyloid-β

KW - Aβ oligomer

KW - Curcumin

KW - Inflammation

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84978492694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978492694&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-802972-5.00023-8

DO - 10.1016/B978-0-12-802972-5.00023-8

M3 - Chapter

AN - SCOPUS:84978492694

SN - 9780128029725

SP - 487

EP - 505

BT - Fruits, Vegetables, and Herbs: Bioactive Foods in Health Promotion

PB - Elsevier Inc.

ER -